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Abstract 
Background:  Infection is a potentially life-threatening complication of cardiac device 
implantation.  Lead-associated endocarditis may be the most serious complication since it 
is associated with a high mortality.   
Methods:  The medical records of patients referred to our institution for the treatment of 
lead associated endocarditis between 1999 and 2007 were reviewed. 
Results:  A total of 51 of 107 patients referred for device related infections met the 
criteria for lead-associated endocarditis.  Of these, 19 occurred within 6 months of their 
most recent procedure (early), while the remaining 32 occurred more than 6 months later 
(mean= 31.9 months post procedure).  Devices included pacemakers in 33 patients and 
ICDs in 18 patients.  The most common organism responsible for infection was 
Staphylococcus aureus (53%) followed by coagulase-negative staphylocci (22%) and 
streptococci (12%).  Methicillin-resistant Staphylococcus aureus (MRSA), accounted  for 
67% of the s. aureus infections.  Coagulase-negative staphylococci were responsible for 
only 26% of early and 19% of late cases.  A distant site of infection was common 
(26/51=51%), particularly in patients with MRSA LAE.  The device and leads were 
removed percutaneously in all patients.  Only 1 patient failed to respond to intravenous 
antibiotics.  
Conclusions:  Our data suggests that methicillin-resistant Staphylococcus aureus is an 
important pathogen in lead-associated endocarditis.  Since many infections occur months 
after the last device procedure, hematogenous spread of organisms from a distant site 
may be an important contributing factor.  These data suggest that strategies to prevent 
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hematogenous infection, particularly with Staphylococcus aureus, are critical in patients 
with implantable cardiac devices.  
 
KEY WORDS:  endocarditis, device infections, pacemaker, implantable cardioverter-
defibrillator, Staphylococcus aureus, lead extraction 
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Introduction 
Infection is a potentially life-threatening complication of cardiac device implantation.  
In previous reports, the rate of infection varies from 0.13-19.9%.1,2,3,4  The severity of 
infection ranges from localized infection in the device pocket to systemic infection 
associated with bacteremia and endocarditis.  Lead associated-endocarditis (LAE) is the 
most serious complication related to cardiac device implantation with mortality ranging 
from 10-21%.2,5,6,7,8,9,10  Previous reports have emphasized skin flora as the likely source 
for LAE.  Coagulase-negative staphylococci are reported as the most likely organisms 
followed by Staphylococcus aureus.  These reports are from an earlier period, before the 
importance of antibiotic-resistant organisms such as methicillin-resistant Staphylococcus 
aureus (MRSA) was emphasized.  We hypothesized that MRSA may account for a 
greater percentage of device-related infections than previously reported.  Therefore, we 
retrospectively reviewed cases of LAE referred to our institution to evaluate the clinical 
presentation, microbiology, and course of these patients. 
 
Methods 
We performed a retrospective review of the medical records of patients with lead-
associated endocarditis referred to Thomas Jefferson University Hospital between 1999 
and 2007.  The study proposal was approved by the Institutional Review Board. 
Definitions 
A diagnosis of infective endocarditis was based on the modified Duke criteria.11 
Specifically, lead-associated endocarditis was defined as persistent bacteremia in the 
presence of a vegetation documented by echocardiography, a vegetation without 
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bacteremia in a patient treated with antibiotics, or persistent unexplained bacteremia 
without any another identifiable source.  In patients with fever and persistent unexplained 
bacteremia, a diagnosis of LAE was presumed since bacteremia and fever resolved 
promptly upon removal of the device and leads despite the absence of a vegetation on 
imaging.  A vegetation was defined as an oscillating intracardiac mass on the electrode 
leads or cardiac leaflets which was present in more than one echocardiographic plane.  
For the purposes of this analysis, early LAE was defined as infection occurring within six 
months of implantation or device replacement.  If infection occurred more than six 
months following surgery, it was defined as late LAE. 
 
Diagnosis and Treatment 
Multiple blood cultures were obtained in each patient.  A transthoracic 
echocardiogram was initially performed in all patients.  If a vegetation was not present by 
transthoracic echocardiogram, a trans-esophageal echocardiogram was performed.   
All patients underwent removal and extraction of all hardware.  Prior to extraction, all  
patients had a temporary transvenous pacemaker placed via a femoral vein.  A bacterial 
culture was performed on the pulse generator site.  Following the procedure, intravenous 
antibiotics, based on the results of culture and sensitivity, were administered for a total of 
six weeks. If bacterial cultures were unrevealing, empiric antimicrobials were prescribed 
intravenously for six weeks.  A new device was implanted on the contralateral side (if 
clinically indicated), once the patient had received at least 14 days of appropriate 
intravenous antibiotics.  Relapse was defined as a recurrence of infection with the same 
organism. 
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Results 
Baseline Characteristics 
A total of 107 patients with device-related infections were referred to our center 
during the study period.  Of these, 51 cases met the criteria for LAE and are included in 
this report. (Table I) 
The mean age of the patients was 68±11 years (range 42 to 83 years).  Seventy-seven 
percent were male.  Devices included permanent pacemakers in 33 (65%) and ICDs in 18 
(35%).  LAE occurred following the initial implantation in 33 (65%), after a revision or 
upgrade in 8 (15%), and following a pulse generator replacement in the remaining 10 
(20%).  Sixteen patients (31%) had diabetes mellitus, 7 (14%) had chronic renal 
insufficiency (defined as a serum creatinine greater than 3 mg/dl) with 6 of these patients 
requiring chronic hemodialysis, and 2 were on chronic oral steroids. 
The most common presenting symptom was fever (51%).  Eleven patients (22%) 
presented with symptoms resulting from infection at a remote site, while pain at the 
generator site was the predominant complaint in three patients (6%).  The remaining eight 
patients presented with nonspecific complaints such as malaise.  LAE was diagnosed by 
the finding of bacteremia and vegetation in 33, vegetation without bacteremia on 
antibiotics in 1, and persistent bacteremia without any identifiable source in 17.  
The timing of the LAE was divided into two groups based on the timing of the most 
recent device procedure. (Figure 1)  By definition, all early infections occurred within 6 
months of the most recent procedure (N= 19, mean=3 months, range 1-6 months).  Late 
infections occurred a mean of 32 months post procedure (N= 32, range 7-78 months).  
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LAE occurred following a system upgrade or device replacement in 8/19 (42%) early 
cases vs. 10/32 (31%) late cases. 
   
Echocardiography 
Vegetations were visible by echocardiography in 34 patients.  All patients underwent 
transthoracic echocardiography.  However, vegetations were visualized by transthoracic 
echocardiography in only 6 of the patients. In 28 patients, a vegetation was only 
demonstrated by transesophageal echocardiography.  No vegetations were seen in 17 
patients. Vegetations were measured up to 3.5 cm.  Vegetations greater than 2 cm in 
diameter were seen in six patients. 
 
 
Bacteriology 
Blood cultures were positive in 47/51 patients upon presentation to our institution; 
18/19 patients with early LAE and 29/32 patients with late LAE had positive blood 
cultures.  All patients with negative blood cultures had been previously treated with 
intravenous antibiotics prior to hospital admission or transfer.  Overall, 17/51 patients had 
positive pocket or wound cultures.  Seven of 19 (37%) early LAE and 10/32 (31%) late 
LAE patients had positive pocket cultures.  In all cases, the organism responsible for the 
positive pocket culture was identical to the one obtained from the blood culture. 
In the total group of 51 patients, Staphylococcus aureus was the most common cause 
of LAE (53%), followed by coagulase-negative staphylococci (22%) and streptococci 
(12%).  Methicillin resistance was present in 67% of the patients infected with 
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Staphylococcus aureus.  There were differences in bacteriology between early and late 
cases of LAE.  (Figure 2)  Though Staphylococcus aureus was the predominant organism 
in both early and late cases, more early LAE cases had methicillin-resistant organisms 
(83% vs 50%).  Coagulase-negative staphylococci were responsible for only 26% of early 
cases and 19% of late cases. 
A distant site of infection was present in approximately one half of the patients 
(26/51). (Table II)  These sites included infected intravenous catheter sites (23%), wound 
infection or abscess (19%), osteomyelitis (27%), joint infections (12%), and intravenous 
drug use (12%).  Interestingly, 15/18 patients with MRSA (7 EARLY, 8 LATE) had a 
distant site of infection.  In patients with early LAE and MRSA, these sites included 
wound infections in 2 (cervical operative site, sacral decubitus), lumbar abcess in 1, joint 
infection in 2, and history of recent IV drug use in 2.  In patients with late LAE and 
MRSA, the sites included osteomyelitis in 3, infected intravenous catheter in 3, spinal 
abscess following epidural injection for pain in 1, and urosepsis with indwelling catheter 
in 1. 
Outcome 
The device and leads were removed at the time of initial clinical presentation.  The 
entire device system was successfully removed in all patients.  All patients underwent 
percutaneous lead extraction with use of a lead-locking stylet and/or traction (n=24) or a 
laser sheath (n=27).  No patient required surgical extraction.  At the completion of the 
extraction procedure 8 patients remained pacemaker dependent and therefore needed 
continuation of temporary pacing.  Seven of the eight patients had a temporary pacing 
lead inserted via the internal jugular vein contralateral to the extraction site.  The 
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remaining patient received temporary pacing via the lead placed in the femoral vein at the 
start of the procedure.   Three patients received active fixation and four patients received 
passive fixation temporary leads.  The temporary leads remained in place until the time of 
re-implantation.  
The extraction procedure was complicated by cardiac tamponade requiring urgent 
pericardiocentesis in 1 patient and clinical pulmonary emboli in 2 patients.  Two patients 
had pulmonary emboli prior to the extraction procedure despite a negative trans-
esophageal echocardiogram. Neither of these patients had emboli documented post 
procedure.  Clinical pulmonary emboli were not seen any of the patients with vegetations 
measuring greater than 2 cm. in diameter, including the patient with a 3.5 cm vegetation.  
This patient was a 90 year old woman with MRSA bacteremia and renal failure.  It was 
felt that she was too frail and ill to undergo an open extraction procedure. 
Pulmonary emboli were apparent in the 2 patients following the development of post 
operative pleuritic chest pain and transient oxygen desaturation.  In both cases, the 
oxygen saturation promptly returned to baseline with no hemodynamic sequelae.  Both 
patients had vegetations seen on their pacing leads by transesophageal echocardiography 
performed at an outside institution.  The size of these vegetations was not quantified.  
Several days later, one of these patients died following the development of shock due to 
persistent MRSA bacteremia in the presence of a spinal abscess.  It was felt that death 
was not directly related to the extraction procedure.  Two additional patients died during 
the index hospitalization of overwhelming sepsis and not as a result of the extraction 
procedure.  The remaining 48 patients were treated with six weeks of intravenous 
antibiotics.  All patients were assessed for the ongoing need for an implantable cardiac 
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device.  Seventeen patients had their devices re-implanted on the contra lateral side 
during the index hospitalization following at least 14 days of intravenous antibiotics.  An 
additional 2 patients returned following 6 weeks of IV antibiotics for re-implantation on 
the contralateral side.  None received epicardial leads.  Only 1 patient had recurrent LAE.  
This patient had chronic osteomyelitis which may have been the remote source of both 
infections.  The surviving patients were followed for at least six months post procedure 
and had no evidence of recurrent infection. 
 
Discussion 
The rate of implantation of cardiac rhythm management devices continues to grow.  
Between 1990 and 2002, approximately 2.25 million pacemakers and 415,780 
implantable cardioverter-defibrillators (ICD’s) were implanted.12  During this period of 
time the annual number of pacemakers implanted increased three-fold while the number 
of ICDs implanted increased ten-fold.  The estimated rate of infection associated with 
these devices ranges from 0.13-19%1-3  but has increased by 124% during the past 15 
years.13  This may relate to the fact that device-related infection is higher for ICDs than 
pacemakers.14 
Lead associated endocarditis is present in only 10% of device-related infections but is 
associated with high mortality, morbidity and economic cost.3  Prompt recognition and 
management is imperative as 6% of our patients died during the index hospitalization 
despite uncomplicated extraction of their hardware and administration of appropriate 
intravenous antibiotics.  Previous reports have highlighted the importance of skin flora, 
such as coagulase-negative staphylococci as pathogenic organisms in these device 
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infections.  However, while LAE more commonly occurs early post implantation, it may 
occur at any time following implantation or replacement.     The present report highlights 
the changing bacteriology of LAE and the potential importance of LAE stemming from 
distant sites of infection particularly with organisms such as MRSA. 
 
Bacteriology 
The most common pathogens associated with LAE are skin flora.2,3,5,7,9  Previous 
reports suggest that coagulase-negative staphylococci are the predominant organisms in 
approximately 60% of infections with Staphylococcus aureus accounting for an 
additional 20% of cases.  Less common organisms include enteric Gram negative bacilli 
and streptococci.  Klug and co-workers reviewed the clinical presentation and 
management of 52 patients with lead associated endocarditis.7  All patients had 
permanent transvenous pacemakers. None had ICDs.  Fourteen patients were classified as 
an acute infection with infection occurring early post implantation (within 6 weeks) while 
the remaining 38 patients developed infection more than 6 weeks following implantation 
and were classified as chronic infection.  In patients with acute infection, Staphylococcus 
aureus (36%) was the most common organism isolated followed by coagulase-negative 
staphylococci (21%).  By contrast, late infections were most often caused by coagulase-
negative staphylococci (71%) followed by Staphylococcus aureus (13%).  The 
importance of skin flora was stressed along with the subcutaneous site of pacemaker lead 
insertion as the likely portal for infection.  
By contrast, we found that Staphylococcus aureus was the most common pathogen 
responsible for both early and late infections.  We chose to divide LAE infections into 
early and late based on a six month window following the most recent procedure, since 
infection by Staphylococcus aureus arising from contamination of the operative site 
would most likely occur within that time frame.    However, we realize that this cut-off is 
somewhat arbitrary and does not exclude the possibility that LAE after 6 months could 
arise from the operative site.  In our population, Staphylococcus aureus accounted for 
58% of early and 50% of late LAE.  Importantly, MRSA was responsible for 53% of all 
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early LAE and 25% of late LAE.  This highlights the emerging role of this organism in 
LAE.   
Relationship between S.aureus bacteremia and LAE  
 
Most patients who presented with MRSA infection and LAE demonstrated an 
additional remote site of infection.  It is unclear whether these distant sites of infection 
represent the source of LAE or instead represent secondary seeding as a result of the 
LAE.  Our data do suggest, however, that hematogenous spread of organisms, rather than 
local invasion from an infected operative site, is the more likely mechanism for LAE.  
Previous investigators have emphasized the high risk of device infection in patients who 
develop Staphylococcus aureus bacteremia.15  Chamis and co-workers found that cardiac 
device infection occurred in approximately 70% of patients with Staphylococcus aureus 
bacteremia and an implanted cardiac device.  Hematogenous spread of the organism was 
responsible for the infection in 27.3% of cases.  Likewise, Camus and colleagues reported 
that sustained Staphylococcus aureus or coagulase-negative staphylocooci bacteremia 
was associated with device infection in 67% of their patients.16  We found that 67% of 
our patients had no detectable signs of pulse generator pocket infection.  This is in 
agreement with previous reports15,16 which suggest that hematogenous spread of 
Staphylococcus aureus is an important cause of LAE. 
 
Emergence of antibiotic resistant organisms 
Methicillin-resistant staphylococcus aureus has emerged as an important pathogen in 
both hospital acquired and community acquired infections.17,18,19   These infections are 
associated with both a high mortality and morbidity despite improvements in recognition 
and antibiotic treatment.  The rise in the incidence of Staphylococcus aureus infections 
parallels the increase in the use of intravascular devices and implantable devices.17  
Although many of our patients were hospitalized for the treatment of noncardiac issues 
and developed infected intravenous or dialysis catheters or wound infections, a number 
developed MRSA in non-hospital settings (e.g. following IV drug abuse, paraspinal 
abscess following epidural analgesia, and osteomyelitis). 
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The reason for the increase in Staphylococcus aureus infections in patients with 
cardiac devices is not clear.  One factor may relate to the increase in ICDs as a percentage 
of cardiac device implants.12  As compared to patients with permanent pacemakers,   ICD 
patients generally have more co-morbidities such as heart failure and renal failure.  Such 
comorbidities, make them more likely to be hospitalized or have invasive procedures 
which may expose them to organisms such as staphylococcus aureus. 
 
Treatment and outcome 
Prompt recognition of LAE, treatment with intravenous antibiotics, and removal of all 
device hardware is important to a successful outcome.2,3,5,7,8,9,10  It has been suggested 
that intravenous vancomycin be administered initially until a specific pathogen has been 
identified since it is generally effective against MRSA.20  The choice of antibiotics may 
then be changed to the most appropriate antibiotic once the final results of culture and 
sensitivity are obtained.  Previous investigators have stressed that transvenous extraction 
may be performed safely.  Re-implantation is possible following a course of intravenous 
antibiotics.  However, the timing of re-implantation is open to question.  Seventeen of our 
patients had re-implantation of their device during the index hospitalization, following a 
course of fourteen days of intravenous antibiotics.  One patient with a history of 
osteomyelitis had recurrent LAE.  This suggests that prolonged administration of 
intravenous antibiotics may be necessary in patients with alternate sites of infection, such 
as bone, which generally require a long course of antibiotics for successful treatment.  In 
cases where the offending source is easily treated or removed, such as an intravenous 
catheter or port, re-implantation may be possible following a shorter course of antibiotics. 
All of our patients underwent percutaneous lead extraction.  Patients with large 
vegetations may be at particular risk for pulmonary emboli.  In these patients, 
thoracotomy and removal under direct vision should be considered.2,3  However, in 
patients who are critically ill and at high risk for thoracotomy and general anesthesia, 
percutaneous extraction remains an appropriate option.  Of interest is the fact that 6 of 
our patients had vegetations measuring greater than 2 cm in diameter.  All had their leads 
safely extracted without clinical pulmonary emboli, including the patient with a 3.5 cm 
vegetation. 
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Limitations 
The results of this investigation may be influenced by referral bias since we are a  
tertiary care center for lead extraction.  Our population was quite ill with many co-
morbidities and had a high incidence of Staphylococcus aureus bacteremia and LAE.  In 
addition, LAE represented approximately one-half of those patients referred for treatment 
of device related infections.  It is likely that many more patients with localized infection 
were cared for at their local institution.  Therefore, other centers may not have the same 
experience.  Nonetheless, the marked increase in staphylococcus aureus as the cause for 
LAE along with the high incidence of MRSA suggests that the bacteriology of LAE may 
be changing. 
The diagnosis of LAE may be difficult to establish, particularly in patients with 
persistent, unexplained bacteremia on antibiotics who have no vegetation detectable by 
echocardiography.  We are confident that our 17 patients with persistent unexplained 
bacteremia had LAE since their fever and bacteremia promptly resolved upon removal of 
the implantable device and leads.  The possibility that rapid clinical improvement had 
nothing to due with device and lead removal cannot be completely excluded. 
Conclusions 
Infection, particularly lead-associated endocarditis, is a serious, life-threatening 
complication of cardiac device implantation.  Prompt recognition and management is 
essential for improving outcome.  Our data suggests that methicillin-resistant 
Staphyloccus aureus has emerged as an important pathogen.  Since LAE is common in 
patients who develop Staphylococcus aureus bacteremia, strategies to prevent 
intravenous infection and hematogenous spread of organisms is critical in patients with 
implantable cardiac devices. 
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Figure Legends: 
 
Figure 1   Timing of Lead-Associated Endocarditis (LAE):  The timing of LAE (in 
months) with respect to the most recent procedure is displayed on a logarithmic scale for 
both Early and Late endocarditis.  Late LAE occurred a mean of 31.9 months following 
the most recent procedure. 
 
Figure 2A: Bacteriology of Early LAE:  Staphylococci species accounted for most early 
LAE.  MRSA was the predominant organism.  Abbreviations:  MRSA=  Methicillin-
resistant staphylococcus aureus, MSSA=Methicillin-sensitive staphylococcus aureus,  
CoNS= coagulase-negative staphylococcus, Strep= streptococcus. 
 
Figure 2 B:  Bacteriology of Late LAE:  Similar to early LAE, Staphylococci were the 
predominant organisms responsible for late LAE.  Though MSSA was more common, 
MRSA was responsible for 50% of staphylococcus aureus infections.  Abbreviations:  
same as Figure 2 A 
 
17 
TABLE I:  Demographics 
 
Age (years) 68+11  
 
% Male 77  
Cardiac device   
 
Permanent Pacemaker 33 (65%) 
 
ICD 18 (35%) 
Most recent procedure   
 Primary implant 33 (65%) 
 Upgrade or revision 8 (15%) 
 Replacement 10 (20%) 
 
 
 
 
TABLE II:  Sites of Remote Infection n= 26 
 
Source Total Early LAE n=9 Late  LAEn=17 
Intravenous Catheter 6 (23%) 1 5 
Wound infection/abscess 5 (19%) 3 2 
Osteomyelitis 7 (27%) - 7 
IV drug use 3 (12%) 2 1 
Joint infection 3 (12%) 2 1 
Other 2 (7%) 1 1 
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